RESPREEZA 4 g pdr et solv p sol inj
7680653370069
CH-65337
B02AB02
06.01.1.
Active substances:
1 / 3
google
Details
- Product number
- 6533702
- CPT
- -
- Packaging group
- 2
- Unit
- Durchstechflasche(n)
- Composition
- Praeparatio cryodesiccata: alpha-1-proteinasi inhibitor humanum 4000 mg, natrii chloridum, natrii dihydrogenophosphas monohydricus, mannitolum, acidum hydrochloridum, natrii hydroxidum, pro vitro corresp. natrium 148 mg. Solvens: aqua ad iniectabile 76 ml, pro vitro.
Articles (1)
Respreeza 50 mg/ml à 4 g, Pulver und Lösungsmittel zur Herstellung einer i.v. Infusionslösung
Pulver
2
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
aqua ad iniectabile
|
76.0 ML | Substance | HNIDK |
|
alpha-1-proteinasi inhibitor humanum
|
4000.0 MG | Substance | Wirkstoff (Principe actif) |
|
natrii chloridum
|
- | Substance | HNIDK |
|
natrii dihydrogenophosphas monohydricus
|
- | Substance | HNIDK |
|
mannitolum
|
- | Substance | HNIDK |
|
acidum hydrochloridum
|
- | Substance | HNIDK |
|
natrii hydroxidum
|
- | Substance | HNIDK |
|
natrium
|
148.0 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 1325.80
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/11/2020
Authorization holder
CSL Behring AG
3014 Bern
Authorization information
- Swissmedic authorization number
- 65337
- Drug name
- Respreeza, Pulver und Lösungsmittel zur Herstellung einer i.v. Infusionslösung
- Galenic form
- PULMI
- ATC Code
- B02AB02
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 21/01/2016
- Authorization expiration date
- 31/12/9999
- IT number
- 06.01.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- RESPREEZA 4 g pdr et solv p sol inj
- Description (DE)
- RESPREEZA 4 g Pulv und Lsm zur Inj Lsg
- Market launch
- 16/05/2019
- Narcotic (BTM)
- No